Press release

BIOTRONIK Launches New Peripheral PTA Portfolio

Buelach, Switzerland (14 January 2008). BIOTRONIK announced today the launch of Passeo-18 and Passeo-35 in Europe. With these products, BIOTRONIK launches a specific PTA range of products for endovascular treatment of the inflow and outflow vessels.

New Over-The-Wire catheters with small balloon diameters and long lengths dedicated for infra popliteal and femoral angioplasty allow BIOTRONIK to complement the existing portfolio of low profile devices including PRO-Kinetic Explorer (balloon expandable Cobalt Chromium stent) and Astron Pulsar (self expanding Nitinol stent) and Elect Explorer (fast exchange balloon)

Passeo-35 is the next generation 0.035” OTW balloon system, compatible with 5 Fr sheaths up to a diameter of 7mm diameter and 6 Fr compatible up to 10mm diameter.

Passeo-18 is a 0.018”, OTW balloon system, compatible with 4 Fr sheaths. The complete range covers diameters from 2.5 to 4.0 mm with lengths up to 170mm for challenging infrapopliteal cases and diameters from 5.0 to 7.0 mm for femoral use.

Alain Aimonetti, Vice President of BIOTRONIK Vascular Intervention comments: ”This new portfolio is a milestone in the endovascular treatment of patients with CLI (Critical Limb Ischemia) and offers the interventionalist a significant extension of therapy options for limb salvage, it also confirms BIOTRONIK’s Peripheral Product strategy to offer the full portfolio of devices and our commitment to be “Best in Class” with all new devices for peripheral intervention.”



BIOTRONIK is a leading European manufacturer of medical technology with a worldwide market presence. The company offers a complete line of products for diagnosis, treatment and advanced therapy support in the areas of cardiac rhythm management, electrophysiology and vascular intervention.

The vascular intervention product range consists of guide wires, balloon catheters and stent systems for coronary and peripheral applications. BIOTRONIK invests heavily in research and development and is committed to pursuing future-oriented approaches to cardiovascular and peripheral vascular therapy.


Press Release


Contact Information

Your Question or Comment